Triptorelin

Pharmacologic Category

Gonadotropin Releasing Hormone Agonist

Dosing: Adult

Prostate cancer (advanced): Trelstar: IM:

3.75 mg once every 4 weeks or

11.25 mg once every 12 weeks or

22.5 mg once every 24 weeks

Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) (adjunctive therapy): Decapeptyl (Canadian product): Females: SubQ: Usual dose: 0.1 mg once daily initiated on day 2 or 3 or days 21 to 23 of menstrual cycle (or 5 to 7 days prior to expected onset of menses). Dose may be adjusted according to ovarian response as measured by ovarian ultrasound with or without serum estradiol levels. Treatment is continued until follicles achieve suitable size (typically 4 to 7 weeks).

Endometrial stromal sarcoma (off-label use): IM: 3.75 mg once every 28 days for ~3 to 5 months (Jin 2015). Additional studies are necessary to further define the role of triptorelin in the management of this condition.

Endometriosis (off-label use): IM: 3.75 mg once every 4 weeks for a total of 6 doses (Bergqvist 1998; Choktanasiri 1996) or 3.75 mg once every 6 weeks for a total of 4 doses (Tse 2000) or 11.25 mg once every 3 months (Donnez 2004). Hormonal add-back therapy (such as estrogens or progestins) is recommended at the start of treatment to reduce bone mineral loss (Dunselman 2014; SOGC [Leyland 2010]). Duration of therapy is not well established (Dunselman 2014) but should be evaluated after 3 months (SOGC [Leyland 2010]); in general, use of GnRH agonists is limited to less than 6 or 12 months due to adverse events (Leone Roberti Maggiore 2014).

Treatment of paraphilia/hypersexuality (off-label use) (Guay 2009; Thibaut 1993): Males:

Note: May cause an initial increase in androgen concentrations, which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1 to 2 months (Guay 2009). Avoid use in patients with osteoporosis or active pituitary pathology.

SubQ: Test dose: 1 mg (observe for hypersensitivity); if tolerated, follow with monthly IM injections

IM: 3.75 mg monthly

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling. However, renal impairment increases systemic exposure to triptorelin.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling. However, hepatic impairment increases systemic exposure to triptorelin.

Dosing: Pediatric

Central precocious puberty: Children ≥2 years: Triptodur: IM: 22.5 mg once every 24 weeks; discontinue therapy at appropriate age of onset of puberty.

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, in adult patients, renal impairment increased systemic exposure to triptorelin.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, in adult patients, hepatic impairment increased systemic exposure to triptorelin.

Use: Labeled Indications

Central precocious puberty: Triptodur: Treatment of central precocious puberty in patients 2 years and older

Prostate cancer (advanced): Trelstar: Palliative treatment of advanced prostate cancer

Assisted reproductive technologies: Decapeptyl [Canadian product]: Adjunctive therapy in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART)

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Endometrial stromal sarcomaLevel of Evidence [C, G]

Data from a limited number of case reports and clinical experience suggest triptorelin may be beneficial in the treatment of endometrial stromal sarcoma Ref. Clinical experience also suggests the utility of gonadotropin-releasing hormone receptor analogs, including triptorelin may be of benefit in the treatment of endometrial stromal sarcoma Ref. Additional studies are necessary to further define the role of triptorelin in the management of this condition.

EndometriosisLevel of Evidence [C, G]

Data from a small multicenter clinical trial and from a small randomized, double blind, placebo control study suggest that triptorelin may be beneficial in the treatment of endometriosis Ref.

Based on the American College of Obstetricians and Gynecologists (ACOG) Management of Endometriosis Guidelines and the Society of Obstetricians and Gynaecologists of Canada (SOGC) Endometriosis Diagnosis and Management Guidelines, empiric therapy with a GnRH agonist is effective (as second-line therapy) in the management of pain associated with endometriosis once other causes have been excluded and treatment with preferred initial therapies have failed Ref.

Paraphilia/hypersexualityLevel of Evidence [G]

Based on The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias, triptorelin given for paraphilia/hypersexuality is an effective and recommended treatment option in the management of this condition.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

American Society of Clinical Oncology (ASCO)/Cancer Care Ontario Practice Guideline, "Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer," September 2014

American Society for Reproductive Medicine (ASRM), Ovarian Hyperstimulation Syndrome, 2016

Society of Obstetricians and Gynaecologists of Canada (SOGC) and Canadian Fertility and Andrology Society, Diagnosis and Management of Ovarian Hyperstimulation Syndrome, 2011

Society of Obstetricians and Gynaecologists of Canada (SOGC), Prevention of Ovarian Hyperstimulation Syndrome, 2014

Administration: IM

Administer by IM injection into the buttock (Trelstar) or into the buttock or thigh (Triptodur); alternate injection sites. Administer immediately after reconstitution. Must administer under the supervision of a health care provider.

Administration: Subcutaneous

Decapeptyl [Canadian product] is administered by subcutaneous injection into the lower abdomen; alternate injection sites. If a dose is missed, it can be administered on the same day; however, do not double doses. Must administer under the supervision of a health care provider.

Administration: Pediatric

IM: Administer Triptodur by IM injection into the buttock or thigh; alternate injection sites.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

For IM preparation, double gloves, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) are recommended. Double gloving and a protective gown are required during IM administration (NIOSH 2016).

Storage/Stability

Trelstar: Store at 20°C to 25°C (68°F to 77°F). Do not freeze MIXJECT system. Administer immediately after reconstitution.

Triptodur: Store at 20°C to 25°C (68°F to 77°F). Do not freeze.

Decapeptyl [Canadian product]: Store at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light.

Preparation for Administration: Adult

MixJect System: Follow manufacturer's instructions for mixing prior to use.

Trelstar: Reconstitute with 2 mL sterile water for injection. Shake well to obtain a uniform suspension. Solution will appear milky. Administer immediately after reconstitution.

Triptodur: Reconstitute with 2 mL sterile water for injection. Agitate the vial for 30 to 60 seconds to obtain a milky and homogenous suspension. Administer immediately after reconstitution to avoid separation of the suspension. Refer to manufacturer’s labeling for detailed preparation instructions.

Preparation for Administration: Pediatric

Parenteral: Triptodur: Reconstitute with 2 mL sterile water for injection. Gently swirl the vial. Solution will appear milky. Administer immediately after reconstitution.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat prostate cancer.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Sexual dysfunction

• Hot flashes

• Nausea

• Injection site irritation

• Trouble sleeping

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Pituitary apoplexy like sudden headache, vomiting, passing out, mood changes, eye weakness, unable to move eyes, or vision changes

• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit

• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain

• Severe cerebrovascular disease like change in strength on one side is greater than the other, trouble speaking or thinking, change in balance, or vision changes

• Chest pain

• Shortness of breath

• Excessive weight gain

• Swelling of arms or legs

• Trouble urinating

• Severe headache

• Severe dizziness

• Passing out

• Vision changes

• Back pain

• Blood in the urine

• Burning or numbness feeling

• Fast heartbeat

• Abnormal heartbeat

• Chills

• Sore throat

• Behavioral changes

• Mood changes

• Severe muscle pain

• Severe joint pain

• Severe loss of strength and energy

• Trouble moving

• Muscle weakness

• Bone pain

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Triptodur: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208956s000lbl.pdf#page=12

Contraindications

Known hypersensitivity to triptorelin or any component of the formulation, other GnRH agonists or GnRH; pregnancy

Canadian labeling: Additional contraindications (not in the US labeling): Breastfeeding women

Warnings/Precautions

Concerns related to adverse effects:

• Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). Myocardial infarction, sudden cardiac death and stroke have been reported in men receiving GnRH agonists. ADT may prolong the QT/QTc interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QTc prolongation, congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients with medications known to prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients.

• Decreased bone density: Use with caution in patients with risk factors for decreased bone mineral density; GnRH agonist therapy may increase risk for osteoporosis and bone fractures particularly with prolonged use.

• Hyperglycemia: Hyperglycemia and an increased risk of developing diabetes has been reported with therapy and may manifest as diabetes or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) as clinically necessary.

• Hypersensitivity reactions: Angioedema and anaphylactic shock have occurred; discontinue use if severe reaction occurs.

• Ovarian hyperstimulation syndrome: Decapeptyl [Canadian product]: Ovarian hyperstimulation syndrome (OHSS) is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011). Therapy with gonadotropins should be stopped.

• Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually <2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.

• Psychiatric effects: Symptoms of emotional lability (eg, crying, irritability, anger, aggression, impatience) have been reported with GnRH agonists, including triptorelin; monitor for the development or worsening of psychiatric symptoms.

• Seizures: Seizures have been reported with GnRH agonists, including triptorelin in patients with or without a history of seizures or other conditions or concurrent medications associated with seizures.

• Spinal cord compression: Cases of spinal cord compression, which may contribute to weakness or paralysis (possible fatal complications), have been reported; observe patients with metastatic vertebral lesions closely during the first few weeks of treatment.

• Symptom flare: Transient initial increases in gonadotropins and sex steroids leading to a worsening of symptoms may be observed during the first few weeks of therapy or after subsequent doses. Patients with prostate cancer may experience new or increased bone pain, neuropathy, hematuria, or urethral or bladder outlet obstruction. Female patients with central precocious puberty may experience transient vaginal bleeding.

Disease-related concerns:

• Urinary tract obstruction: Observe patients with urinary tract obstruction closely during the first few weeks of treatment.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Dosage form specific issues:

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

No dosage adjustments are needed in the elderly. Monitoring for bone density changes, serum lipid, hemoglobin A1c, blood pressure, and serum calcium changes is recommended.

Reproductive Considerations

When used for assisted reproductive technologies (ART; not an approved use in the US), pregnancy must be ruled out prior to therapy and nonhormonal contraception should be used until menses occurs. Due to the short half-life of triptorelin (formulations used for ART), it is not expected to be present in the maternal serum at the time of embryo transfer.

Based on the mechanism of action, may impair fertility in males of reproductive potential.

Pregnancy Considerations

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to triptorelin may cause fetal harm.

Hormonal changes that occur with therapy may increase the risk of pregnancy loss. Therefore, use is contraindicated in females who are pregnant. Information following inadvertent exposure in early pregnancy is limited (Elefant 1995).

Breast-Feeding Considerations

It is not known if triptorelin is present in breast milk.

Due to the potential for adverse reactions in the breastfed infant, the manufacturer recommends that a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.

Adverse Reactions

>10%:

Endocrine & metabolic: Hot flash (prostate cancer: 59% to 73%; central precocious puberty: 2% to 5%), increased serum glucose (prostate cancer)

Hematologic & oncologic: Decreased hemoglobin (prostate cancer), decreased red blood cells (prostate cancer)

Hepatic: Increased serum alanine aminotransferase (prostate cancer), increased serum aspartate aminotransferase (prostate cancer), increased serum transaminases (prostate cancer)

Local: Pain at injection site (central precocious puberty: 45%; prostate cancer: 4%), erythema at injection site (central precocious puberty: 14%)

Nervous system: Headache (2% to 14%)

Neuromuscular & skeletal: Skeletal pain (prostate cancer: 12% to 13%)

Renal: Increased blood urea nitrogen (prostate cancer)

Respiratory: Nasopharyngitis (central precocious puberty: 14%)

1% to 10%:

Cardiovascular: Lower extremity edema (prostate cancer: 6%), hypertension (prostate cancer: ≤4%; central precocious puberty), chest pain (prostate cancer: 2%), peripheral edema (prostate cancer: 1%)

Dermatologic: Injection site pruritus (central precocious puberty: 2%), skin rash (prostate cancer: 2%), pruritus (prostate cancer: 1%)

Endocrine & metabolic: Decreased libido (prostate cancer: 2%), dependent edema (prostate cancer: 2%), gynecomastia (prostate cancer: 2%)

Gastrointestinal: Gastroenteritis (central precocious puberty: 7%), nausea (prostate cancer: 3%), anorexia (prostate cancer: 2%), constipation (prostate cancer: 2%), dyspepsia (prostate cancer: 2%), vomiting (prostate cancer: 2%), abdominal pain (prostate cancer: 1%), diarrhea (prostate cancer: 1%)

Genitourinary: Erectile dysfunction (prostate cancer: 10%), menstruation (central precocious puberty: 8%), testicular atrophy (prostate cancer: 8%), impotence (prostate cancer: 2% to 7%), dysuria (prostate cancer: 5%), mastalgia (prostate cancer: 2%), urinary retention (prostate cancer: 1%), urinary tract infection (prostate cancer: 1%)

Hematologic & oncologic: Anemia (prostate cancer: 1%)

Hepatic: Increased serum alkaline phosphatase (≥2%), hepatic insufficiency (prostate cancer: 1%)

Infection: Influenza (central precocious puberty: 5%)

Local: Swelling at injection site (central precocious puberty: 2%)

Nervous system: Pain (prostate cancer: 2% to 3%), dizziness (prostate cancer: 1% to 3%), anxiety (central precocious puberty: 2%), fatigue (prostate cancer: 2%), mood changes (central precocious puberty: 2%), insomnia (prostate cancer: ≤2%), emotional lability (≤1%)

Neuromuscular & skeletal: Lower extremity pain (prostate cancer: 2% to 5%), back pain (prostate cancer: ≤3%), lower limb cramps (prostate cancer: 2%), arthralgia (prostate cancer: ≤2%), asthenia (prostate cancer: 1%), myalgia (prostate cancer: 1%)

Ophthalmic: Conjunctivitis (prostate cancer: 1%), eye pain (prostate cancer: 1%)

Otic: Otitis externa (central precocious puberty: 5%)

Respiratory: Upper respiratory tract infection (central precocious puberty: 9%), cough (central precocious puberty: 7%; prostate cancer: 2%), bronchitis (central precocious puberty: 5%), pharyngitis (central precocious puberty: 5%; prostate cancer: 1%), sinusitis (central precocious puberty: 5%), dyspnea (prostate cancer: 1%)

Miscellaneous: Postoperative pain (reproductive studies: 3% to 4%), missed abortion (reproductive studies: 2%)

Frequency not defined: Endocrine & metabolic: Increased testosterone level

<1%, postmarketing, and/or case reports: Altered gonadal hormone levels (pituitary-gonadal axis suppression), anaphylactic shock, anaphylactoid shock, angioedema, cerebrovascular accident, deep vein thrombosis, hypersensitivity reaction, interstitial pulmonary disease, intracranial hypertension (Tan 2019), limb pain, myocardial infarction, pituitary apoplexy, pulmonary embolism, seizure, thrombophlebitis, transient ischemic attacks, urticaria, visual disturbance, visual impairment

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• GnRH Agonist Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. Risk C: Monitor therapy

Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. Risk X: Avoid combination

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. Risk X: Avoid combination

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Test Interactions

Pituitary-gonadal function may be suppressed with chronic administration and for up to 8 weeks after triptorelin therapy has been discontinued.

Monitoring Parameters

Glucose and HbA1c (periodically), signs and symptoms of emerging cardiovascular disease; consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients; development/worsening of psychiatric symptoms.

Additional monitoring (per indication):

Treatment of precocious puberty: Monitor response to therapy with LH levels after a GnRH or GnRH agonist stimulation test, basal LH, or serum sex steroid levels beginning 1 to 2 months after initiation of therapy, during therapy, and with each subsequent dose; height every 3 to 6 months; bone age (periodically)

Prostate cancer: Serum testosterone levels, prostate-specific antigen; bone density.

Assisted reproductive technologies: Decapeptyl [Canadian product]: Negative pregnancy test prior to initiation of therapy; signs/symptoms of allergic reaction for 30 minutes after administration; ultrasound and/or estradiol levels to assess follicle development; ultrasound to assess number and size of follicles

OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011).

Treatment of paraphilia/hypersexuality (off-label use): The following monitoring has been recommended for other GnRH agonists: CBC (baseline, monthly for 4 months then every 6 months); serum testosterone (baseline, monthly for 4 months then every 6 months); serum LH (baseline and every 6 months), FSH (baseline), serum BUN and creatinine (baseline and every 6 months); bone density (baseline and yearly); ECG (baseline) (Reilly 2000)

Advanced Practitioners Physical Assessment/Monitoring

Hypersensitivity reactions, including angioedema, anaphylaxis, and anaphylactic shock, have rarely occurred; discontinue if severe reaction occurs. Be alert to the potential onset of spinal cord compression, diabetes, and/or cardiovascular disease.

Nursing Physical Assessment/Monitoring

Hypersensitivity reactions, including angioedema, anaphylaxis, and anaphylactic shock, have rarely occurred; discontinue if severe reaction occurs.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Suspension Reconstituted, Intramuscular:

Trelstar: 3.75 mg (1 ea [DSC]); 11.25 mg (1 ea [DSC]) [contains polysorbate 80]

Trelstar Mixject: 3.75 mg (1 ea [DSC]); 11.25 mg (1 ea [DSC]); 22.5 mg (1 ea [DSC]) [contains polysorbate 80]

Suspension Reconstituted, Intramuscular [preservative free]:

Trelstar Mixject: 3.75 mg (1 ea); 11.25 mg (1 ea); 22.5 mg (1 ea) [contains polysorbate 80]

Suspension Reconstituted ER, Intramuscular:

Triptodur: 22.5 mg (1 ea) [contains polysorbate 80]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Prefilled Syringe, Subcutaneous:

Decapeptyl: 0.1 mg/mL (1 mL)

Suspension Reconstituted, Intramuscular:

Trelstar: 3.75 mg (1 ea); 11.25 mg (1 ea); 22.5 mg (1 ea) [contains polysorbate 80]

Anatomic Therapeutic Chemical (ATC) Classification

• L02AE04

Generic Available (US)

No

Pricing: US

Suspension (reconstituted) (Trelstar Mixject Intramuscular)

3.75 mg (per each): $975.89

11.25 mg (per each): $2,927.66

22.5 mg (per each): $5,855.33

Suspension Reconstituted ER (Triptodur Intramuscular)

22.5 mg (per each): $20,172.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Triptorelin is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. After chronic and continuous administration, usually 2 to 4 weeks after initiation, a sustained decrease in LH and FSH secretion occurs. When used for assisted reproductive technologies (ART), prevents premature LH surge in women undergoing controlled ovarian hyperstimulation.

Pharmacodynamics/Kinetics

Distribution: Vd: 30 to 33 L

Protein binding: None

Metabolism: Unknown; unlikely to involve CYP; no known metabolites

Half-life elimination: 2.8 ± 1.2 hours

Moderate-to-severe renal impairment: 6.6 to 7.7 hours

Hepatic impairment: 7.6 hours

Time to peak: Trelstar: 1 to 3 hours; Triptodur: 4 hours

Excretion: Urine (42% as intact peptide); hepatic

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: There is a decrease in total Cl proportional to decrease in CrCl and increased Vd and half-life. Patients with renal impairment had 2- to 4-fold higher exposure (AUC) values than younger healthy men.

Hepatic function impairment: The decrease in triptorelin Cl is more pronounced. Triptorelin half-life increase is similar to renal impairment. Patients with hepatic impairment had 2- to 4-fold higher exposure (AUC) values than younger healthy men.

Geriatric: Triptorelin clearance is partly correlated to total CrCl, which is well known to decrease with age.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

Although significant myelosuppression with associated altered hemostasis has been reported for many chemotherapeutic agents, myelosuppression is not common with triptorelin and no specific precautions appear to necessary.

Related Information

• Safe Handling of Hazardous Drugs

Index Terms

AY-25650; CL-118,532; D-Trp(6)-LHRH; Detryptoreline; Triptodur; Triptorelin Embonate; Triptorelin Pamoate; Tryptoreline

FDA Approval Date

June 15, 2000

References

Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010;116(1):223-236. doi: 10.1097/AOG.0b013e3181e8b073.[PubMed 20567196]

Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188-1198. doi: 10.1016/S1470-2045(09)70226-8.[PubMed 19959075]

Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436-3448.[PubMed 25199761]

Bergqvist A, Bergh T, Hogström L, Mattsson S, Nordenskjöld F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril. 1998;69(4):702-708.[PubMed 9548161]

Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol. 2004;104(5 Pt 2):1182-1184. doi: 10.1097/01.AOG.0000133533.05148.aa.[PubMed 15516445]

Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm.[PubMed 6423951]

Choktanasiri W, Boonkasemsanti W, Sittisomwong T, et al. Long-acting triptorelin for the treatment of endometriosis. Int J Gynaecol Obstet. 1996;54(3):237-243.[PubMed 8889631]

Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.[PubMed 25574681]

Decapeptyl (triptorelin) [product monograph]. North York, Ontario, Canada: Ferring Inc; July 2012.

Donnez J, Dewart PJ, Hedon B, et al. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. Fertil Steril. 2004;81(2):297-304. doi: 10.1016/j.fertnstert.2003.07.013.[PubMed 14967363]

Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-412. doi:10.1093/humrep/det457.[PubMed 24435778]

Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F. Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline. Fertil Steril. 1995;63(5):1111-1113.[PubMed 7720926]

ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii92-vii99. doi: 10.1093/annonc/mds253.[PubMed 22997462]

Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol. 2012;10:32. doi: 10.1186/1477-7827-10-32.[PubMed 22531097]

Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther. 2009;31(1):1-31.[PubMed 19243704]

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Jin Y, Li Y, Deng CY, et al. Fertility-sparing treatment of low-grade endometrial stromal sarcoma. Int J Clin Exp Med. 2015;8(4):5818-5821.[PubMed 26131171]

Joint Society of Obstetricians and Gynaecologists of Canada -Canadian Fertility and Andrology Society (SOGC-CFAS ) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. Int J Gynaecol Obstet. 2012;116(3):268-273.[PubMed 22416285]

Leone Roberti Maggiore U, Scala C, Remorgida V, et al. Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother. 2014;15(8):1153-1179. doi: 10.1517/14656566.2014.916279.[PubMed 24832495]

Levine GN, D’Amico AV, Berger P, et al, “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association,” Circulation, 2010, 121:831-38.[PubMed 20124128]

Leyland N, Casper R, Laberge P, Singh SS; SOGC. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32(7 Suppl 2):S1-S32.[PubMed 21545757]

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.[PubMed 27678032]

Reilly DR, Delva NJ, and Hudson RW, “Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,” Can J Psychiatry, 2000, 45(6):559-63.[PubMed 10986575]

Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes [published online November 18, 2019]. Am J Clin Dermatol.[PubMed 31741184]

Thibaut F, Cordier B, and Kuhn JM, “Effect of a Long-Lasting Gonadotrophin Hormone-Releasing Hormone Agonist in Six Cases of Severe Male Paraphilia,” Acta Psychiatr Scand, 1993, 87(6):445-50.[PubMed 8356897]

Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM; WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry. 2010;11(4):604-655.[PubMed 20459370]

Trelstar (triptorelin) [prescribing information]. Irvine, CA: Allergan USA Inc; December 2018.

Trelstar (triptorelin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma Co; July 2016.

Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2018.

Tse CY, Chow AM, Chan SC. Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study. Hong Kong Med J. 2000;6(3):260-264.[PubMed 11025843]

US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.

Brand Names: International

Arvekap (GR); Decapeptyl (AE, AR, BE, BG, BH, CL, CN, CO, CY, CZ, DE, EC, EG, ES, FR, GB, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MY, NL, OM, PL, PT, PY, RU, SA, SK, SY, TR, UA, UY, VE, YE); Decapeptyl CR (AE, CY, EG, HR, IL, IQ, IR, JO, KR, KW, LB, LY, MY, NZ, OM, SA, SG, SY, TH, YE); Decapeptyl Daily (IN); Decapeptyl Depot (AT, CZ, DE, DK, EE, FI, IN, IS, KR, LT, SE, SK); Decapeptyl LA (EC); Decapeptyl LP (FR); Decapeptyl Retard (CH); Decapeptyl SR (BH, PK); Decapetyl (LK); Diphereline (AU, LV, RO, SG, TH, UA, VN); Diphereline PR (HK, KR, MY, PH, TH, TW); Fertipeptil (VN); Gonapeptyl (AE, BE, FR, GB, IE, JO, LB, MT, PY, RO, VN); Gonapeptyl CR (BH, QA); Gonapeptyl Daily (BR, CR, DO, GT, HN, NI, PA, SV); Gonapeptyl Depot (CR, CU, DO, GT, HN, NI, PA, SV); Gonapeptyl,CR (LB); GonapeptylCR (SA); Neo Decapeptyl (BR); Neo-Decapeptyl CR (PE); Pamorelin (CR, DO, GT, HN, NI, NO, PA, PH, SV); Salvacyl (BE, GB)

Last Updated 5/6/20